Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries

• Main Authors: Prashant Kumar (Author), Ravi S. Shukla (Author), Ashaben Patel (Author), Swathi R. Pullagurla (Author), Christopher Bird (Author), Oluwadara Ogun (Author), Ozan S. Kumru (Author), Ahd Hamidi (Author), Femke Hoeksema (Author), Christopher Yallop (Author), Julie E. Bines (Author), Sangeeta B. Joshi (Author), David B. Volkin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Formulation development was performed with the live, attenuated, human neonatal rotavirus vaccine candidate (RV3-BB) with three main objectives to facilitate use in low- and middle- income countries including (1) a liquid, 2-8°C stable vaccine, (2) no necessity for pre-neutralization of gastric acid...